MeiraGTx Holdings (MGTX) Income from Continuing Operations (2017 - 2025)
MeiraGTx Holdings' (MGTX) quarterly Income from Continuing Operations came in at 14595000.0 in Q4 2025, up 143.97% YoY from 5982322.59 in Q4 2024, and up 129.81% on a QoQ basis from 48955000.0 in Q3 2025.
MeiraGTx Holdings (MGTX) Income from Continuing Operations (2017 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Income from Continuing Operations data on file, last reported at 14595000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 143.97% year-over-year to 14595000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 123407000.0 (up 29.35% YoY) and the FY2025 annual result came in at 287191000.0, up 7.19% from the prior year.
- Income from Continuing Operations improved to 14595000.0 in Q4 2025, from 48955000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 14595000.0 in Q4 2025 to a low of 51047000.0 in Q2 2024.
- A 5-year average of 29538300.0 and a median of 32339500.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 605.16% — and 2025, when it soared 143.97%.
- Tracing MGTX's Income from Continuing Operations over 5 years: stood at 7785000.0 in 2021, then sank by 439.02% to 41963000.0 in 2022, then jumped by 115.66% to 6571000.0 in 2023, then tumbled by 605.16% to 33194000.0 in 2024, then soared by 143.97% to 14595000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 14595000.0 (Q4 2025), 48955000.0 (Q3 2025), and 41421000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | MeiraGTx Holdings | 1.10 Bn | 1.03 Bn | - | 16.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.60 Mn |
| Sep 30, 2025 | -48.96 Mn |
| Jun 30, 2025 | -41.42 Mn |
| Mar 31, 2025 | -47.63 Mn |
| Dec 31, 2024 | -33.19 Mn |
| Sep 30, 2024 | -41.50 Mn |
| Jun 30, 2024 | -51.05 Mn |
| Mar 31, 2024 | -48.93 Mn |
| Dec 31, 2023 | 6.57 Mn |
| Sep 30, 2023 | -35.62 Mn |
| Jun 30, 2023 | -31.49 Mn |
| Mar 31, 2023 | -34.28 Mn |
| Dec 31, 2022 | -41.96 Mn |
| Sep 30, 2022 | -24.41 Mn |
| Jun 30, 2022 | -25.08 Mn |
| Mar 31, 2022 | -30.09 Mn |
| Dec 31, 2021 | -7.79 Mn |
| Sep 30, 2021 | -23.75 Mn |
| Jun 30, 2021 | -21.67 Mn |
| Mar 31, 2021 | -23.13 Mn |